Trial Profile
An open-label, parallel group, single session study comparing the pharmacokinetics of a single oral dose of GW876008 administered to healthy volunteer smokers and healthy volunteer non-smokers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Aug 2023
Price :
$35
*
At a glance
- Drugs Emicerfont (Primary)
- Indications Anxiety disorders; Depressive disorders; Irritable bowel syndrome
- Focus Pharmacokinetics
- Sponsors GSK
- 22 Jun 2007 Status changed from in progress to completed.
- 04 Mar 2007 New trial record.